Are drugs too expensive in Canada?;Les médicaments au Canada, sont-ils trop chers?

Canadian Family Physician

Volumn 52, Issue MAY, 2006, Pages 573-576

  Lexchin, Joel ^a,b,c,d   Williams, Russell ^d,e   Marion, Jean ^e  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canada's Research Based Pharmaceuticals Companies ^*  (Canada)

^e Canada's Research Based Pharmaceutical Companies (Rx and D)   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ADVERTIZING; ARTICLE; CANADA; CAPITAL; COMMERCIAL PHENOMENA; DRUG CLASSIFICATION; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; GOVERNMENT; INVESTMENT; PRIVATE HEALTH INSURANCE; TAX; TELECOMMUNICATION; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; FEE; HUMAN; RESEARCH; TREATMENT OUTCOME;

CANADA; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; DRUG THERAPY; FEES, PHARMACEUTICAL; HUMANS; RESEARCH; TREATMENT OUTCOME;

EID: 33745211217     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. United states Department of Commerce ITA. Pharmaceutical price controls in OECD countries: implications for U.S. consumers, pricing, research and development and innovation. Washington, DC: National Technical Information Service; 2004.
2. Patented Medicine Prices Review Board. PMRPB annual report 2004. Ottawa, Ont: Patented Medicine Prices Review Board; 2005.
3. DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
4. Light DW, Warburton RN. Extraordinary claims require extraordinary evidence. J Health Econ 2005;24:1030-2.
5. United States Food and Drug Administration. CDER NDAs approved in calendar years 1990-2004 by therapeutic potential and chemical type: Rockville, Md: United States Food and Drug Administration; 2005. Available at: http://www.fda.gov/cder/rdmt/pstable.htm. Accessed 2005 April 20.
6. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-42.
7. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002;20(Suppl 3):11-29.
8. Prescrire International. Industrial interests versus public health: the gap is growing. Prescrire Int 2004;13(70):71-6.
9. World Health Organization. Drug promotion database: what impact does pharmaceutical promotion have on behaviour? Geneva, Switz: World Health Organization, Department of Essential Drugs and Medicines Policy; 2003. Available at: http://www.who.int/entity/medicines/areas/rational_use/ drugPromodhai.pdf. Accessed 2006 April 4.
10. Statistics Canada. Financial performance indicators for Canadian business. Ottawa, Ont: Statistics Canada; 1996. Report no. 61F0058XPE.
11. Lichtenberg F. Benefits and costs of newer drugs: an update. Cambridge, Mass: National Bureau of Economic Research; 2002. Working document no. 8996.
12. Canadian Institute for Health Information. CIHI national health expenditure trends 1975-2004. CIHI news release. Ottawa, Ont: Report Brogan Inc, Rx&D Files; 2004.
13. Patented Medicine Prices Review Board. PMPRB annual report 2004. Ottawa, Ont: Government of Canada; 2004.
14. Organization for Economic Co-operation and Development. OECD Health Data 2005. Paris, Fr: Organization for Economic Co-operation and Development; 2005.
15. Crémieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K. Public and private pharmaceutical spending as determinants of health outcomes in Canada [published erratum appears in Health Econ 2005;14:117]. Health Econ 2005;14:107-16.
16. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
17. Centre for Medicines Research International Ltd (UK). R&D compendium 2004. Epsom, UK: Centre for Medicines Research International Ltd; 2004.
18. Kola I, Landis J. Can the pharmaceutical industry reduce the attrition rate? Nat Rev Drug Discov 2004;3(8):711-6.
19. Grabowski H, Vernon J, DiMasi J. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002;20(Suppl 3):11-29.
20. DiMasi JA, Paquette C. The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics 2004;22(Suppl 2):1-14.
21. United States Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. FDA Report March 2004. Rockville, Md: United States Food and Drug Administration; 2004. Available at: http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html. Accessed 2005 December 1.
22. European Federation of Pharmaceutical Industries and Associations. The Innovative Medicines Initiative, strategic research agenda. Brussels, Belgium: European Commission; 2005. Available at: http://europa.eu.int/ comm/research/fp6/index_en.cfm?p=1_innomed. Accessed 2005 December 1.
23. Statistics Canada, Science Statistics. Estimate of total spending on research and development in the health field in Canada, 1998 to 2004. Ottawa, Ont: Statistics Canada; 2005.